Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes: constipation-predominant, diarrhea-predominant, and mixed. ICD codes for IBS include a variety of subtypes; this analysis covers constipation-predominant IBS (IBS-C) and IBS without diarrhea. Limited treatment options are available, and only a few drugs have FDA approval for IBS-C. Current treatments include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan’s Linzess and Synergy Pharmaceutical’s Trulance), bicyclic fatty acids (Takeda’s Amitiza and Par’s generic lubiprostone), and sodium/ hydrogen exchanger 3 (NHE3) inhibitors (Ardelyx’s Ibsrela). These treatments are only moderately effective. Zelnorm, a 5-HT4 receptor agonist, was relaunched in 2019 for IBS-C in women younger than age 65 but was removed from the market again in 2022 for business-related reasons.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Allergan, Synergy Pharmaceuticals, Takeda, Alfasigma
Key drugs: Ibsrela, Linzess, Trulance, Amitiza, lubiprostone (generic), Zelnorm, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic antidepressants
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.